TransCode Therapeutics (RNAZ)
(Delayed Data from NSDQ)
$0.68 USD
-0.06 (-8.11%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $0.68 0.00 (0.13%) 6:12 PM ET
4-Sell of 5 4
F Value B Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.68 USD
-0.06 (-8.11%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $0.68 0.00 (0.13%) 6:12 PM ET
4-Sell of 5 4
F Value B Growth C Momentum D VGM
Zacks News
Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
TransCode (RNAZ) Down 50% on Issue of New Common Stock
by Zacks Equity Research
TransCode Therapeutics (RNAZ) will issue secondary shares and warrants, diluting its current shareholder base. The company plans to raise $7.5 million in gross proceeds from this issue.
TransCode Therapeutics Inc. (RNAZ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
TransCode Therapeutics Inc. (RNAZ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.